Personalized dose reduction strategies for biologic disease-modifying antirheumatic drugs for treating axial spondyloarthritis: a clinical and economic evaluation with predictive modeling.

Journal: BMC rheumatology
Published Date: May 26, 2025

Abstract

BACKGROUND: Axial spondyloarthritis (AS) is a chronic inflammatory disease that significantly affects quality of life and imposes a high economic burden on patients due to the cost of biologic disease-modifying antirheumatic drugs (bDMARDs). Dose reduction strategies for bDMARDs may offer a feasible approach to maintaining clinical efficacy while reducing costs. This study aimed to evaluate the clinical effectiveness and cost-efficiency of bDMARD dose reduction in patients with AS and apply machine learning to identify key factors influencing disease control.

Authors

  • Bui Hai Binh
    Centre of Rheumatology, Bach Mai Hospital, Hanoi, 100000, Vietnam.
  • Nguyen Thi Thu Phuong
    Faculty of Pharmacy & Biomedical-Pharmaceutical Sciences Research Group, Hai Phong University of Medicine and Pharmacy, Hai Phong, Vietnam.
  • Vu Thi Thanh Hang
    Centre of Rheumatology, Bach Mai Hospital, Hanoi, 100000, Vietnam.
  • Ngo Thi Thuc Nhan
    Nam Dinh University of Nursing, Nam Dinh, 420000, Vietnam.
  • Nguyen Thi Nhu Hoa
    Centre of Rheumatology, Bach Mai Hospital, Hanoi, 100000, Vietnam.
  • Hoang Van Dung
    Department of Internal Medicine, Hai Phong International Hospital, Hai Phong, 180000, Vietnam. dungnoitru26@gmail.com.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals